Objective To investigate the efficacy of acrivastine combined with loratadine in the treatment of chronic refractory urticaria. Methods A total of 88 patients with chronic refractory urticaria were selected from January 2022 to January 2023 in Chaihudian Town Hospital of Tengzhou City, and they were divided into control group and experimental group by random number table method, with 44 patients in each group. The reference group was treated with loratadine, and the experimental group was treated with acrivastine combined with loratadine. The symptom scores, laboratory related indicators and quality of life were compared between the two groups. Results After intervention, the symptom score of the experimental group was lower than that of the reference group, the difference was statistically significant (P